These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 34459148)

  • 41. Synthesis and SAR of a new series of COX-2-selective inhibitors: pyrazolo[1,5-a]pyrimidines.
    Almansa C; de Arriba AF; Cavalcanti FL; Gómez LA; Miralles A; Merlos M; García-Rafanell J; Forn J
    J Med Chem; 2001 Feb; 44(3):350-61. PubMed ID: 11462976
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Structure-based design, synthesis and biological evaluation of a newer series of pyrazolo[1,5-a]pyrimidine analogues as potential anti-tubercular agents.
    Modi P; Patel S; Chhabria M
    Bioorg Chem; 2019 Jun; 87():240-251. PubMed ID: 30908967
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Pre-steady-state kinetics and solvent isotope effects support the "billiard-type" transport mechanism in Na
    Malinen AM; Anashkin VA; Orlov VN; Bogachev AV; Lahti R; Baykov AA
    Protein Sci; 2022 Sep; 31(9):e4394. PubMed ID: 36040263
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Structure-activity relationships of compounds targeting mycobacterium tuberculosis 1-deoxy-D-xylulose 5-phosphate synthase.
    Mao J; Eoh H; He R; Wang Y; Wan B; Franzblau SG; Crick DC; Kozikowski AP
    Bioorg Med Chem Lett; 2008 Oct; 18(19):5320-3. PubMed ID: 18783951
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Synthesis and in-vitro anti-proliferative evaluation of some pyrazolo[1,5-a]pyrimidines as novel larotrectinib analogs.
    Attia MH; Elrazaz EZ; El-Emam SZ; Taher AT; Abdel-Aziz HA; Abouzid KAM
    Bioorg Chem; 2020 Jan; 94():103458. PubMed ID: 31785854
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Pyrazolo[3,4-d]pyrimidine-based dual EGFR T790M/HER2 inhibitors: Design, synthesis, structure-activity relationship and biological activity as potential antitumor and anticonvulsant agents.
    Lamie PF; El-Kalaawy AM; Abdel Latif NS; Rashed LA; Philoppes JN
    Eur J Med Chem; 2021 Mar; 214():113222. PubMed ID: 33545637
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Discovery of pyrazolo[3,4-d]pyrimidine derivatives as GPR119 agonists.
    Gillespie P; Goodnow RA; Saha G; Bose G; Moulik K; Zwingelstein C; Myers M; Conde-Knape K; Pietranico-Cole S; So SS
    Bioorg Med Chem Lett; 2014 Feb; 24(3):949-53. PubMed ID: 24412066
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Identification of a new family of pyrazolo[3,4-d]pyrimidine derivatives as multitarget Fyn-Blk-Lyn inhibitors active on B- and T-lymphoma cell lines.
    Fallacara AL; Passannanti R; Mori M; Iovenitti G; Musumeci F; Greco C; Crespan E; Kissova M; Maga G; Tarantelli C; Spriano F; Gaudio E; Bertoni F; Botta M; Schenone S
    Eur J Med Chem; 2019 Nov; 181():111545. PubMed ID: 31400706
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Pyrazolo[3,4-d]pyrimidine derivatives containing a Schiff base moiety as potential antiviral agents.
    Wang YY; Xu FZ; Zhu YY; Song B; Luo D; Yu G; Chen S; Xue W; Wu J
    Bioorg Med Chem Lett; 2018 Sep; 28(17):2979-2984. PubMed ID: 30122226
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Synthesis, antibacterial activity and cytotoxicity of new fused pyrazolo[1,5-a]pyrimidine and pyrazolo[5,1-c][1,2,4]triazine derivatives from new 5-aminopyrazoles.
    Al-Adiwish WM; Tahir MI; Siti-Noor-Adnalizawati A; Hashim SF; Ibrahim N; Yaacob WA
    Eur J Med Chem; 2013 Jun; 64():464-76. PubMed ID: 23669354
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Design, synthesis and evaluation of some pyrazolo[3,4-d]pyrimidines as anti-inflammatory agents.
    Tageldin GN; Fahmy SM; Ashour HM; Khalil MA; Nassra RA; Labouta IM
    Bioorg Chem; 2018 Aug; 78():358-371. PubMed ID: 29627656
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The discovery of potent, orally bioavailable pyrazolo and triazolopyrimidine CXCR2 receptor antagonists.
    Porter DW; Bradley M; Brown Z; Canova R; Charlton S; Cox B; Hunt P; Kolarik D; Lewis S; O'Connor D; Reilly J; Spanka C; Tedaldi L; Watson SJ; Wermuth R; Press NJ
    Bioorg Med Chem Lett; 2014 Jan; 24(1):72-6. PubMed ID: 24332493
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Synthesis and biological evaluation of pyrazolo[3,4-b]pyridine-3-yl pyrimidine derivatives as sGC stimulators for the treatment of pulmonary hypertension.
    Li L; Zhang W; Lin F; Lu X; Chen W; Li X; Zhou X; Su R; Wang L; Zheng Z; Li S
    Eur J Med Chem; 2019 Jul; 173():107-116. PubMed ID: 30995566
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Novel pyrazolo[3,4-d]pyrimidines: design, synthesis, anticancer activity, dual EGFR/ErbB2 receptor tyrosine kinases inhibitory activity, effects on cell cycle profile and caspase-3-mediated apoptosis.
    Maher M; Kassab AE; Zaher AF; Mahmoud Z
    J Enzyme Inhib Med Chem; 2019 Dec; 34(1):532-546. PubMed ID: 30688116
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Structure-based optimization of pyrazolo[3,4-d]pyrimidines as Abl inhibitors and antiproliferative agents toward human leukemia cell lines.
    Manetti F; Brullo C; Magnani M; Mosci F; Chelli B; Crespan E; Schenone S; Naldini A; Bruno O; Trincavelli ML; Maga G; Carraro F; Martini C; Bondavalli F; Botta M
    J Med Chem; 2008 Mar; 51(5):1252-9. PubMed ID: 18257513
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Synthesis and anti-tumor activities of novel pyrazolo[1,5-a]pyrimidines.
    Li J; Zhao YF; Zhao XL; Yuan XY; Gong P
    Arch Pharm (Weinheim); 2006 Nov; 339(11):593-7. PubMed ID: 17036367
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Design and synthesis of 3-(2-pyridyl)pyrazolo[1,5-a]pyrimidines as potent CRF1 receptor antagonists.
    Huang CQ; Wilcoxen KM; Grigoriadis DE; McCarthy JR; Chen C
    Bioorg Med Chem Lett; 2004 Aug; 14(15):3943-7. PubMed ID: 15225703
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Design, synthesis and antitumor evaluation of novel 5-methylpyrazolo[1,5-a]pyrimidine derivatives as potential c-Met inhibitors.
    Luo G; Ma Y; Liang X; Xie G; Luo Y; Zha D; Wang S; Yu L; Zheng X; Wu W; Zhang C
    Bioorg Chem; 2020 Nov; 104():104356. PubMed ID: 33142417
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Fused heterocyclic compounds bearing bridgehead nitrogen as potent HIV-1 NNRTIs. Part 1: design, synthesis and biological evaluation of novel 5,7-disubstituted pyrazolo[1,5-a]pyrimidine derivatives.
    Tian Y; Du D; Rai D; Wang L; Liu H; Zhan P; De Clercq E; Pannecouque C; Liu X
    Bioorg Med Chem; 2014 Apr; 22(7):2052-9. PubMed ID: 24631361
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Novel 3-alkoxy-1H-pyrazolo[3,4-d]pyrimidines as EGFR and erbB2 receptor tyrosine kinase inhibitors.
    Ducray R; Ballard P; Barlaam BC; Hickinson MD; Kettle JG; Ogilvie DJ; Trigwell CB
    Bioorg Med Chem Lett; 2008 Feb; 18(3):959-62. PubMed ID: 18182285
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.